1. JohannesonB, LimaG, von SalomeJ, Alarcon-SegoviaD, Alarcon-RiquelmeME (2002) A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am J Hum Genet 71: 1060–1071.
2. WuH, BoackleSA, HanvivadhanakulP, UlgiatiD, GrossmanJM, et al. (2007) Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proc Natl Acad Sci U S A 104: 3961–3966.
3. GatevaV, SandlingJK, HomG, TaylorKE, ChungSA, et al. (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41: 1228–1233.
4. FrankeA, McGovernDP, BarrettJC, WangK, Radford-SmithGL, et al. (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42: 1118–1125.
5. FrankeA, BalschunT, KarlsenTH, SventoraityteJ, NikolausS, et al. (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40: 1319–1323.
6. AndersonCA, BoucherG, LeesCW, FrankeA, D'AmatoM, et al. (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43: 246–252.
7. BarrettJC, ClaytonDG, ConcannonP, AkolkarB, CooperJD, et al. (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41: 703–707.
8. PlagnolV, HowsonJM, SmythDJ, WalkerN, HaflerJP, et al. (2011) Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet 7: e1002216.
9. RemmersEF, CosanF, KirinoY, OmbrelloMJ, AbaciN, et al. (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 42: 698–702.
10. MizukiN, MeguroA, OtaM, OhnoS, ShiotaT, et al. (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 42: 703–706.
11. HofmannSR, Rosen-WolffA, TsokosGC, HedrichCM (2012) Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol 143: 116–127.
12. PestkaS, KrauseCD, SarkarD, WalterMR, ShiY, et al. (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929–979.
13. ParkYB, LeeSK, KimDS, LeeJ, LeeCH, et al. (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16: 283–288.
14. HoussiauFA, LefebvreC, Vanden BergheM, LambertM, DevogelaerJP, et al. (1995) Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4: 393–395.
15. LlorenteL, Richaud-PatinY, Garcia-PadillaC, ClaretE, Jakez-OcampoJ, et al. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790–1800.
16. LlorenteL, Richaud-PatinY, CoudercJ, Alarcon-SegoviaD, Ruiz-SotoR, et al. (1997) Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 40: 1429–1435.
17. GrondalG, KristjansdottirH, GunnlaugsdottirB, ArnasonA, LundbergI, et al. (1999) Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 42: 1649–1654.
18. BeebeAM, CuaDJ, de Waal MalefytR (2002) The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 13: 403–412.
19. OkamotoA, FujioK, OkamuraT, YamamotoK (2011) Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011: 463412.
20. GladmanDD, UrowitzMB, KagalA, HallettD (2000) Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 27: 377–379.
21. YeeCS, FarewellVT, IsenbergDA, GriffithsB, TehLS, et al. (2011) The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 50: 982–988.
22. LavaurJ, BernardF, TrifilieffP, PascoliV, KappesV, et al. (2007) A TAT-DEF-Elk-1 peptide regulates the cytonuclear trafficking of Elk-1 and controls cytoskeleton dynamics. J Neurosci 27: 14448–14458.
23. BanchereauJ, PascualV (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383–392.
24. van der LindenMW, WestendorpRG, SturkA, BergmanW, HuizingaTW (2000) High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med 48: 327–334.
25. GrondalG, KristjansdottirH, GunnlaugsdottirB, ArnasonA, LundbergI, et al. (1999) Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 42: 1649–1654.
26. EskdaleJ, WordsworthP, BowmanS, FieldM, GallagherG (1997) Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 49: 635–639.
27. MehrianR, QuismorioFPJr, StrassmannG, StimmlerMM, HorwitzDA, et al. (1998) Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 41: 596–602.
28. D'AlfonsoS, RampiM, BocchioD, ColomboG, Scorza-SmeraldiR, et al. (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43: 120–128.
29. MokCC, LanchburyJS, ChanDW, LauCS (1998) Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 41: 1090–1095.
30. RoodMJ, KeijsersV, van der LindenMW, TongTQ, BorggreveSE, et al. (1999) Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis 58: 85–89.
31. GibsonAW, EdbergJC, WuJ, WestendorpRG, HuizingaTW, et al. (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166: 3915–3922.
32. TrynkaG, SandorC, HanB, XuH, StrangerBE, et al. (2013) Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 45: 124–130.
33. SharrocksAD (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827–837.
34. RaoVN, ReddyES (1994) elk-1 proteins interact with MAP kinases. Oncogene 9: 1855–1860.
35. LiW, MarshallC, MeiL, DzubowL, SchmultsC, et al. (2005) Srcasm modulates EGF and Src-kinase signaling in keratinocytes. J Biol Chem 280: 6036–6046.
36. SharmaA, CallahanLM, SulJY, KimTK, BarrettL, et al. (2010) A neurotoxic phosphoform of Elk-1 associates with inclusions from multiple neurodegenerative diseases. PLoS One 5: e9002.
37. MorrisJF, SulJY, KimMS, Klein-SzantoAJ, SchochetT, et al. (2013) Elk-1 phosphorylated at threonine-417 is present in diverse cancers and correlates with differentiation grade of colonic adenocarcinoma. Hum Pathol 44: 766–776.
38. GrammerAC, FischerR, LeeO, ZhangX, LipskyPE (2004) Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 6: 28–38.
39. WongCK, WongPT, TamLS, LiEK, ChenDP, et al. (2009) Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 29: 738–746.
40. BesnardA, Galan-RodriguezB, VanhoutteP, CabocheJ (2011) Elk-1 a transcription factor with multiple facets in the brain. Front Neurosci 5: 35.
41. OdrowazZ, SharrocksAD (2012) ELK1 uses different DNA binding modes to regulate functionally distinct classes of target genes. PLoS Genet 8: e1002694.
42. LiJC, LauAS (2007) A role for mitogen-activated protein kinase and Ets-1 in the induction of interleukin-10 transcription by human immunodeficiency virus-1 Tat. Immunology 121: 337–348.
43. LeeCG, KwonHK, SahooA, HwangW, SoJS, et al. (2012) Interaction of Ets-1 with HDAC1 represses IL-10 expression in Th1 cells. J Immunol 188: 2244–2253.
44. HanJW, ZhengHF, CuiY, SunLD, YeDQ, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41: 1234–1237.
45. YangW, ShenN, YeDQ, LiuQ, ZhangY, et al. (2010) Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. PLoS Genet 6: e1000841.
46. EyquemS, CheminK, FasseuM, ChopinM, SigauxF, et al. (2004) The development of early and mature B cells is impaired in mice deficient for the Ets-1 transcription factor. Eur J Immunol 34: 3187–3196.
47. WangD, JohnSA, ClementsJL, PercyDH, BartonKP, et al. (2005) Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. Int Immunol 17: 1179–1191.
48. GrenninglohR, KangBY, HoIC (2005) Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. J Exp Med 201: 615–626.
49. MoisanJ, GrenninglohR, BettelliE, OukkaM, HoIC (2007) Ets-1 is a negative regulator of Th17 differentiation. J Exp Med 204: 2825–2835.
50. LlorenteL, Richaud-PatinY, WijdenesJ, Alcocer-VarelaJ, MaillotMC, et al. (1993) Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 4: 421–427.
51. LlorenteL, Richaud-PatinY, FiorR, Alcocer-VarelaJ, WijdenesJ, et al. (1994) In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37: 1647–1655.
52. al-JanadiM, al-DalaanA, al-BallaS, al-HumaidiM, RaziuddinS (1996) Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 16: 198–207.
53. CsiszarA, NagyG, GergelyP, PozsonyiT, PocsikE (2000) Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 122: 464–470.
54. NakanoS, MorimotoS, SuzukiJ, NozawaK, AmanoH, et al. (2008) Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 47: 145–149.
55. SchickelJN, PasqualiJL, SoleyA, KnappAM, DecossasM, et al. (2012) Carabin deficiency in B cells increases BCR-TLR9 costimulation-induced autoimmunity. EMBO Mol Med 4: 1261–1275.
56. RoussetF, GarciaE, DefranceT, PeronneC, VezzioN, et al. (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89: 1890–1893.
57. LlorenteL, Richaud-PatinY (2003) The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20: 287–289.
58. YangM, RuiK, WangS, LuL (2013) Regulatory B cells in autoimmune diseases. Cell Mol Immunol 10: 122–132.
59. BlairPA, Chavez-RuedaKA, EvansJG, ShlomchikMJ, EddaoudiA, et al. (2009) Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. J Immunol 182: 3492–3502.
60. HaasKM, WatanabeR, MatsushitaT, NakashimaH, IshiuraN, et al. (2010) Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 184: 4789–4800.
61. WatanabeR, IshiuraN, NakashimaH, KuwanoY, OkochiH, et al. (2010) Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 184: 4801–4809.
62. ScapiniP, LamagnaC, HuY, LeeK, TangQ, et al. (2011) B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Proc Natl Acad Sci U S A 108: E823–832.
63. TeichmannLL, KashgarianM, WeaverCT, RoersA, MullerW, et al. (2012) B cell-derived IL-10 does not regulate spontaneous systemic autoimmunity in MRL.Fas(lpr) mice. J Immunol 188: 678–685.
64. BlairPA, NorenaLY, Flores-BorjaF, RawlingsDJ, IsenbergDA, et al. (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32: 129–140.
65. IwataY, MatsushitaT, HorikawaM, DililloDJ, YanabaK, et al. (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117: 530–541.
66. OkadaY, ShimaneK, KochiY, TahiraT, SuzukiA, et al. (2012) A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese. PLoS Genet 8: e1002455.
67. LeeHS, KimT, BangSY, NaYJ, KimI, et al. (2013) Ethnic specificity of lupus-associated loci identified in a genome-wide association study in Korean women. Ann Rheum Dis [Epub ahead of print].
68. YangW, TangH, ZhangY, TangX, ZhangJ, et al. (2013) Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet 92: 41–51.
69. FairfaxBP, MakinoS, RadhakrishnanJ, PlantK, LeslieS, et al. (2012) Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet 44: 502–510.
70. GrundbergE, SmallKS, HedmanAK, NicaAC, BuilA, et al. (2012) Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet 44: 1084–1089.
71. DimasAS, DeutschS, StrangerBE, MontgomerySB, BorelC, et al. (2009) Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325: 1246–1250.
72. StrangerBE, MontgomerySB, DimasAS, PartsL, StegleO, et al. (2012) Patterns of cis regulatory variation in diverse human populations. PLoS Genet 8: e1002639.
73. SzkaradkiewiczA, MarciniakR, Chudzicka-StrugalaI, WasilewskaA, DrewsM, et al. (2009) Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 57: 291–294.
74. WangAH, LamWJ, HanDY, DingY, HuR, et al. (2011) The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol 72: 431–435.
75. KucharzikT, StollR, LugeringN, DomschkeW (1995) Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 100: 452–456.
76. KuhnR, LohlerJ, RennickD, RajewskyK, MullerW (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274.
77. SpencerSD, Di MarcoF, HooleyJ, Pitts-MeekS, BauerM, et al. (1998) The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med 187: 571–578.
78. GlockerEO, KotlarzD, BoztugK, GertzEM, SchafferAA, et al. (2009) Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361: 2033–2045.
79. ScofieldRH, KaufmanKM (2012) Mapping susceptibility gene in systemic lupus erythematosus. Methods Mol Biol 900: 11–24.
80. HochbergMC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
81. PriceAL, PattersonNJ, PlengeRM, WeinblattME, ShadickNA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904–909.
82. HoggartCJ, ParraEJ, ShriverMD, BonillaC, KittlesRA, et al. (2003) Control of confounding of genetic associations in stratified populations. Am J Hum Genet 72: 1492–1504.
83. HoggartCJ, ShriverMD, KittlesRA, ClaytonDG, McKeiguePM (2004) Design and analysis of admixture mapping studies. Am J Hum Genet 74: 965–978.
84. McKeiguePM (2005) Prospects for admixture mapping of complex traits. Am J Hum Genet 76: 1–7.
85. LessardCJ, AdriantoI, KellyJA, KaufmanKM, GrundahlKM, et al. (2011) Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet 88: 83–91.
86. HowieBN, DonnellyP, MarchiniJ (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5: e1000529.
87. GladmanDD, IbanezD, UrowitzMB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288–291.
88. TanW, WuH, ZhaoJ, DerberLA, LeeDM, et al. (2010) A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis Rheum 62: 2864–2875.
89. PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
90. BarrettJC, FryB, MallerJ, DalyMJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.